Abstract 251P
Background
There has been an increase in the number of surviving patients with lung cancer (LC) who may suffer from long-term effects related to oncological treatment, including sexual dysfunction (SD). Our aim was to describe the characteristics of SD in a cohort of Ibero-American patients with LC.
Methods
Analytical observational study on patients with lung cancer included in the LUDICAS study. Between July and December 2023, clinical and demographic variables were collected, as well as measures of sexual function using a questionnaire validated and addressed to each gender. Descriptive and logistic regression analyses were performed. The significance level for P was <0.10 (10%).
Results
At the time of this analysis, 276 patients from 18 hospitals were included. 63% (173) were male, 67% (184) had metastatic disease, and 89% (245) were receiving active treatment. 62% (171) reported the occurrence of SD after starting anticancer treatment and 88% (243) indicated that they thought it is important to be evaluated for this condition. 55% (151) reported the incidence of alterations in sexual response phases, while 9% of patients experienced improvement after discontinuation of oncological treatment and 68% never discontinued treatment. Population characteristics are presented in the table. Statistically significant risk factors for SD were progression from early to metastatic disease OR 1.6 (p 0.08), metastatic disease at diagnosis OR 1.7 (p 0.1), and current smoking OR 1.9 (p 0.09).
Conclusions
Our patients with LC have a high prevalence of sexual dysfunction. It is necessary to continue this research to better define the characteristics and risk factors for this disorder in this population.(Table) Table: 251P
| Characteristics of population | % N 276 |
| Mean Age | 60 years (range 34-70) |
| Residence area | |
| Urban | 81%(224) |
| Rural | 19%(52) |
| Smoking status | |
| Never smoker | 14%(39) |
| Former smoker | 58%(160) |
| Current smoker | 28%(77) |
| Comorbidities | |
| Hypertension | 25%(69) |
| Obesity | 14%(39) |
| Chronic bronchitis | 13%(36) |
| Diabetes mellitus | 10%(27) |
| Time from diagnosis | |
| ≥ 3 years | 24%(66) |
| 1-3 years | 40%(111) |
| <1 year | 36%(99) |
| Frequency of severe disturbances of sexual response | |
| Desire | 16%(44) |
| Arousal | 19%(52) |
| Erection | 48%(132) |
| Orgasm | 38%(105) |
| Sexual satisfaction | 49%(135) |
| Type of treatment | |
| Immunotherapy | 29%(80) |
| Chemo immunotherapy | 22%(61) |
| iTKs | 20%(55) |
| Chemotherapy | 11%(30) |
| Intention of treatment | |
| Neo/adjuvant | 15%(41) |
| Palliative | 75%(124) |
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.